Drug Trial Radar · NCT02074800
A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Feb 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Jun 2008
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 28, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of Part 1 of this study is to assess the safety and tolerability of 2 dose levels (1.4 and 2.8 mg/kg) of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328. The purpose of Part 2 of this study is to access the pharmacokinetics (what the body does to the study medication) comparability of the 1.4 mg/kg dose of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328.
Conditions
- Healthy
Interventions
CNTO 328 (Sp2/0-derived)Drug
Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
CNTO 328 (CHO-derived)Drug
Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
PlaceboDrug
Participants will receive a single-dose of matching placebo intravenously in Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events as a measure of safety and tolerability in Part 1Time frame: Up to Day 199
- Maximum observed serum concentration (Cmax) of CNTO 328 in Part 2Time frame: Day 1 (predose, end of infusion, and postdose at Hours 1, 2, 4, and 8), Days 2 to 6, and Days 8, 15, 22, 29, 36, 43, 50, 71, and 85
- Area under the serum concentration-time curve from Day 0 to Day 84 (AUC 0-84D) of CNTO 328 in Part 2Time frame: Day 1 (predose, end of infusion, and postdose at Hours 1, 2, 4, and 8), Days 2 to 6, and Days 8, 15, 22, 29, 36, 43, 50, 71, and 85
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Lincoln, Nebraska
Site not named
Neptune City, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.